BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 10.7% After Better-Than-Expected Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price rose 10.7% on Friday after the company announced better than expected quarterly earnings. The stock traded as high as $8.62 and last traded at $8.7490. Approximately 2,803,466 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 4,386,014 shares. The stock had previously closed at $7.90.

The biotechnology company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $1.05. The company had revenue of $163.28 million during the quarter, compared to the consensus estimate of $151.32 million. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 69.22%. The company’s quarterly revenue was up 209.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.13) EPS.

Trending Headlines about BioCryst Pharmaceuticals

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings sharply beat expectations — GAAP EPS of $1.12 vs. consensus ~$0.07 and quarter revenue above estimates, signaling much stronger profitability and accelerating top‑line growth; investors likely reacted to the surprise beat. Zacks: Q4 Earnings Beat
• Positive Sentiment: Full‑year 2025 results showed strong ORLADEYO performance (net revenue $601.8M, +38% y/y), supporting ongoing revenue momentum and improving free‑cash expectations. GlobeNewsWire: Full‑Year 2025 Results
• Positive Sentiment: Astria acquisition and accompanying guidance boost BioCryst’s HAE franchise and pipeline positioning, which can drive longer‑term revenue expansion and investor confidence in commercial scale. TipRanks: Astria Acquisition
• Positive Sentiment: Analyst sentiment is constructive — consensus rating described as “Moderate Buy,” which can support further upside as coverage and buy‑side interest increases. American Banking News: Analyst Rating
• Neutral Sentiment: Management’s earnings presentation and call provide detail on profitability drivers and product outlook — useful for due diligence but not an immediate directional surprise. Seeking Alpha: Earnings Presentation
• Neutral Sentiment: Market commentary is debating valuation after the recent rebound — some see upside while others question whether the run is already priced in. Yahoo Finance: Valuation Discussion
• Neutral Sentiment: Reported short‑interest data in feeds appears inconsistent (zeros/NaN) and shouldn’t be relied on; no clear short squeeze signal from the published figures.
• Negative Sentiment: Despite the beats, the company still reported a negative net margin and negative ROE; analysts expect negative FY EPS (~‑0.36), so investors should watch sustainability of profits and future guidance. MarketBeat: Earnings Summary

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Barclays cut their price objective on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 4th. HC Wainwright raised their price target on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 15th. Citizens Jmp reduced their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a research report on Wednesday, November 5th. Needham & Company LLC decreased their price objective on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Finally, Zacks Research lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.64.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 21,773 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $7.65, for a total value of $166,563.45. Following the completion of the sale, the insider owned 398,751 shares of the company’s stock, valued at $3,050,445.15. The trade was a 5.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 183,453 shares of company stock valued at $1,330,965. 5.10% of the stock is owned by insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in BioCryst Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock worth $173,732,000 after buying an additional 482,494 shares in the last quarter. RA Capital Management L.P. bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $123,452,000. Deerfield Management Company L.P. grew its holdings in shares of BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after purchasing an additional 7,477,000 shares in the last quarter. State Street Corp increased its position in shares of BioCryst Pharmaceuticals by 12.9% in the fourth quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock worth $86,371,000 after purchasing an additional 1,265,773 shares during the period. Finally, Janus Henderson Group PLC increased its position in shares of BioCryst Pharmaceuticals by 7,807.2% in the fourth quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock worth $57,791,000 after purchasing an additional 7,310,745 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Up 10.8%

The stock has a 50 day moving average of $7.14 and a 200 day moving average of $7.40. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of 7.29 and a beta of 0.83.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.